Get notified when MBRX files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts
NASDAQ: MBRX Moleculin Biotech, Inc. 8-K

Moleculin Biotech reports Q1 2026 financial results and operational updates

Filed May 15, 2026 · Period ending May 15, 2026 · ~1 min read

Key Changes

  • medium

    Company disclosed financial results for the quarter ended March 31, 2026, along with recent operational highlights. Specific figures and details are contained in the attached press release.

    Item 2.02 verify on EDGAR →
  • medium

    This is a routine quarterly earnings disclosure filed via 8-K. The filing body contains no financial details; investors should review the full press release for actual results and operational updates.

    8-K: Earnings verify on EDGAR →

This preview is just the start — the full report includes the narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (ADMT 10-K) is open in full — no account needed.

Partner

Trade MBRX commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?
View original filing on SEC.gov

Source-verified from EDGAR · Narrative written by AI · May 26, 2026 · How we verify